7TM Pharma Initiates Phase I/II Clinical Trial for TM30339

7TM Pharma A/S has initiated a phase I/II clinical trial for TM30339, selected from the company's novel development program for treatment of obesity. TM30339 is the second clinical development candidate taken into clinical testing from the company's in-house drug discovery programs.

TM30339 works through the Y4 receptor like the natural satiety hormone, Pancreatic Polypeptide, PP, but TM30339 has improved properties over PP. Thus, TM30339 mimics a natural satiety signal from the gastrointestinal tract involved in the regulation of food intake in man. In pre-clinical studies in obese mice, the Y4 receptor selective TM30339 was highly efficacious with respect to long term body weight reduction.

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: +45 39 25 77 77

Email: agger@7tm.com

Or visit www.7tm.com

Home > News & Events > News > 7TM Pharma Initiates Phase I/II Clinical Trial for TM30339
Last updated: 2007-05-01

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

7TM Pharma A/S

7TM Pharma A/S is a privately held company, incorporated in 2000 as spin out from University of Copenhagen by internationally recognized pioneers in 7TM receptor research, Professor Thue W. Schwartz and Dr. Christian E. Elling alongside with industry-experienced Mette Kirstine Agger (CEO). The comp...